As part of our commitment to improving the lives of people living with rare diseases Alexion, AstraZeneca's Rare Disease supports quality, independent Continuing Medical Education (CME) designed to enhance patient care and health outcomes.

This call for grant applications provides public notice of availability of funds to address areas related to the multidisciplinary care of patients with

Deadline for Submission	
Decision Notification	
Primary Area of Focus	Rare Disease
Therapeutic Area	Nephrology - Cardiac Surgery Associated acute kidney injury (CSA-AKI)
Geographic Focus	WorldWide
CGA Code	AX001
Intended Audience	Cardiac surgeons, Nephrologists, Anesthesiologists, Cardiologists
Budget	140.000
Educational Need	**Background:** CSA-AKI occurs in 50% of patients with CKD undergoing cardiac surgery and is the second most common type of AKI among patients in the intensive care unit [1,2]. The complement system plays a prominent role in the complex and multifactorial causes of AKI post cardiac surgery.[3-5] CSA-AKI is associated with high clinical, humanistic and economic burden, and results in increased hospital length of stay and complications from surgery such as need for renal replacement therapy and/or mortality post-surgery.[6,7] Patients experiencing AKI after cardiac surgery have a higher risk of developing long-lasting impairment in renal function, increased risk of morbidity and mortality compared with patients without CSA-AKI.[8-11] There are no efficacious preventative measures or treatments for CSA-AKI that reduce the risk of poor short- and long-term outcomes such as reduced kidney function, need for RRT, and death.[11] Hence, there is a high unmet need for targeted therapies with new mechanism of actions to address this gap. **Educational Need and Professional Practice Gaps:** Given the critical role of complement activation in the pathophysiology of CSA-AKI, we believe it is important that the cardiac surgeons, cardiologists, anesthesiologists and the nephrologists are sufficiently educated on the role of complement in the underlying pathophysiology of CSA-AKI. Moreover, the potential to prevent the both short-term and long-term consequences of AKI in this patient population by targeted disease-modifying therapeutic options. Specifically, • Expand the understanding of the role of the complement in ischemia reperfusion injury induced by cardiopulmonary bypass and as a key driver of disease pathophysiology • Increase awareness and appreciation of clinical, humanistic, and economic burden of CSA-AKI and subsequent MAKE both short term and long term.

	Highlight the importance of a multidisciplinary approach to ensure accurate high risk patient identification, and prevention of AKI as a standard for transforming patient outcomes
Educational Design and Focus	Alexion funding is intended to support multi-modal programs (i.e. with live/virtual and/or enduring components) including but not limited to: • Interactive self-directed programs designed for impactful learner engagement using proven distribution channels
Application Requirements	**Proposal must be independently developed and include the following:** • **Needs Assessment/Gaps/Barriers:** Include a comprehensive, well-referenced needs assessment that provides a detailed description of the educational / practice gaps and barriers of the target audiences. The needs assessment must be independently developed and validated by the educational provider. • **Audience Generation:** Describe methods for reaching the target audience(s) and any unique recruitment methods that will be utilized. • **Educational Strategy:** Provide clearly defined and measurable learning objectives that are clearly designed to address the identified gaps and barriers. The proposal should demonstrate an understanding of instructional design issues as they relate to the gaps in the knowledge, competence, or performance of the targeted audience. • **Program Evaluation and Outcomes:** Provide a description of the outcomes methodology that will be employed to measure the impact of the educational program and how these results will be presented, published, or disseminated. Additionally, describe the methods that will be used to determine the extent to which activity has served to close the identified healthcare gap. Programs should include an outcomes plan of at least Moore's level 4. • **Budget:** Include a detailed budget with rationale, including breakdown of costs for content per activity, out-of-pocket cost per activity and management cost per activity. • **Accreditation:** Programs must be accredited and fully compliant with all ACCME Criteria and Standards for Commercial Support℠.

References

Program Requirements: The Program must be planned and executed as an accredited activity and fully compliant with the criteria and/or standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, or NCCPA. Furthermore, the program will be educational and

nonpromotional in nature and will be planned, designed and implemented in accordance with the U.S. Food and Drug Administration’s Guidance on Industry-Supported Scientific and Educational Activities ("Policy Statement").

The Policy Statement and the ACCME Standards require, among other things, that (i) Institution conduct the Program independently and without control or influence by AstraZeneca over the Program's planning, content (including the selection of speakers or moderators), or execution; (ii) the Program be free of commercial bias for or against any product; (iii) Institution make meaningful disclosure of AstraZeneca support of the Program and any prior relationship between Institution and AstraZeneca, and the relationship, if any, between AstraZeneca and the speakers selected by Institution; and (iv) AstraZeneca not engage in, and Institution not permit any other sponsor to engage in, promotional activities in or near the Program room or advertise its products in any materials disseminated as part of the Program.

In addition, Institution is required by the Policy Statement and, if applicable, accreditation standards to ensure that any product discussions at the Program be accurate, objective, balanced and scientifically rigorous. This includes a balanced discussion of each product and of treatment alternatives, that limitations on data be disclosed, that unapproved uses be identified as such, and that for live presentations there be opportunities for questioning or debate.